amycretin oral (NN9487 oral) / Novo Nordisk - LARVOL DELTA

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study (EASD 2024) - P1 | "Amidst investigations into the potential synergy beyond glucagon-like peptide-1 receptor agonists (GLP-1RAs), the combined efficacy of the amylin analogue cagrilintide and the GLP-1RA semaglutide is being explored as a subcutaneous treatment solution. Daily oral amycretin treatment in adult participants with overweight or obesity and without diabetes demonstrated acceptable safety and tolerability profiles and led to remarkable reductions in body weight over only 12 weeks. Furthermore, the lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment. The results underscore the promising potential of amycretin as an anti-obesity medication and may pave the way for a novel patient-centred weight-management option."

Clinical • P1 data • Diabetes • Metabolic Disorders • Obesity

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=432 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=432 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Novo Nordisk’s oral amycretin tops Wegovy in obesity trial (pharmaphorum) - P1 | N=144 | NCT05369390 | Sponsor: Novo Nordisk A/S | "The oral form has completed a phase 1 study, and Novo Nordisk reported results from the first 16 patients out of a total planned enrolment of 144. After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo, which the company said was around twice the level achieved with Wegovy (semaglutide) at that time point....The company's head of development, Martin Lange Holst, told the meeting that the promising results justify further research and a larger phase 2 trial is planned for the second half of this year, with results expected in around 2026."

New P2 trial • P1 data • P2 data • Metabolic Disorders • Obesity

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - P1 | N=144 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed | N=120 ➔ 36

Enrollment change • Trial completion • Genetic Disorders • Obesity

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: Novo Nordisk A/S | Phase classification: P1 ➔ P1/2

Phase classification • Genetic Disorders • Obesity

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (clinicaltrials.gov) - P1 | N=120 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - P1 | N=116 | Recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: Aug 2023 ➔ Jan 2024

Trial primary completion date • Genetic Disorders • Obesity

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - P1 | N=116 | Recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Jul 2023 ➔ Nov 2023

Trial completion date • Genetic Disorders • Obesity

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - P1 | N=116 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity (clinicaltrials.gov) - P1 | N=116 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity